![Torgny H. Svensson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Torgny H. Svensson
Corporate Officer/Principal chez Karolinska Institutet
Profil
Torgny H.
Svensson is the founder of Independent Pharmaceutica AB, which was founded in 1997.
He held the title of Vice President from 2009 to 2011.
Currently, he is a Professor at Karolinska Institutet.
Postes actifs de Torgny H. Svensson
Sociétés | Poste | Début |
---|---|---|
Karolinska Institutet | Corporate Officer/Principal | - |
Anciens postes connus de Torgny H. Svensson
Sociétés | Poste | Fin |
---|---|---|
Independent Pharmaceutica AB
![]() Independent Pharmaceutica AB Medical DistributorsDistribution Services Independent Pharmaceutica AB is a privately owned company. The major owners are Karolinska Investment Fund, LH Advisory, Sandin &Co and The Foundation for Baltic and East European Studies (Östersjöstiftelsen). Independent Pharmaceutica aims to provide pharmacological solutions for treatment of nicotine addiction. The company is spun out of research from the Karolinska Institutet in Stockholm, Sweden. Tobacco use is the leading preventable cause of morbidity and premature death in the world.Currently over 1.2 billion people smoke worldwide and the number of annual deaths from tobacco-related diseases is over 4 million and rising. The costs for society are huge. With the new vaccine Niccine® against nicotine addiction, the health condition of millions of patients is expected to be improved. | Fondateur | 20/10/2011 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
Independent Pharmaceutica AB
![]() Independent Pharmaceutica AB Medical DistributorsDistribution Services Independent Pharmaceutica AB is a privately owned company. The major owners are Karolinska Investment Fund, LH Advisory, Sandin &Co and The Foundation for Baltic and East European Studies (Östersjöstiftelsen). Independent Pharmaceutica aims to provide pharmacological solutions for treatment of nicotine addiction. The company is spun out of research from the Karolinska Institutet in Stockholm, Sweden. Tobacco use is the leading preventable cause of morbidity and premature death in the world.Currently over 1.2 billion people smoke worldwide and the number of annual deaths from tobacco-related diseases is over 4 million and rising. The costs for society are huge. With the new vaccine Niccine® against nicotine addiction, the health condition of millions of patients is expected to be improved. | Distribution Services |